Evidence map›Paper›PMID 42807069›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Hollow-degree-tuned Prussian blue-mesoporous silica nanoplatforms for chemo-photothermal cancer therapy with preliminary microfluidic perfusion evaluation.

Jingjing Xi, Jingjing Liu, Heyao Zhang, Mengxi Wang, Chenyi Lu, Tinghan Wang, Xijun Piao, Ri Huang, Keyun Ren, Xiao Mei

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingjing XiCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.
Jingjing LiuCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.
Heyao ZhangCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.
Mengxi WangCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.
Chenyi LuCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.
Tinghan WangCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.
Xijun PiaoCatug Biotechnology (Suzhou) Co., Ltd., Suzhou, China.
Ri HuangCatug Biotechnology (Suzhou) Co., Ltd., Suzhou, China.
Keyun RenCatug Biotechnology (Suzhou) Co., Ltd., Suzhou, China.
Xiao MeiCenter of Self-Propelled Nanotechnologies, Suzhou Industrial Park Institute of Services Outsourcing, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Balancing photothermal performance and drug-delivery capacity remains a key challenge in the structural design of multifunctional nanomedicines. Hollowing can increase internal space for drug accommodation but may simultaneously reduce the amount of NIR-absorbing Prussian blue (PB), creating an inherent trade-off between drug-delivery capacity and photothermal performance. Methods: The hollow state of hollow mesoporous Prussian blue (HMPB) nanocubes was regulated by controlled HCl etching, followed by a common mesoporous silica (mSiO Results: Increasing hollowing enhanced DOX loading from 525 to 867 μg⋅mg Conclusion: These results demonstrate that hollow-state engineering provides a practical strategy for balancing competing photothermal and drug-delivery functions in PB-based nanoplatforms.

Indexed as

chemo-photothermal therapydrug deliveryhollow-degree engineeringmesoporous silicamicrofluidic evaluationprussian blue

Identifiers

PMID42807069
PMCPMC13617051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.